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Development and progression of any cancer disease are
the result of various alterations at the cellular and mole-
cular level. This comprises changes in expression of
genes, display of surface molecules, composition of
extracellular matrix, and homing of circulating cells to
the tumor site. Most of these changes occur long before
morphological changes can be detected by conventional
methods.
Molecular imaging is aimed at the non-invasive in vivo
characterization and measurement of these processes to
assess therapy effects more prompt than classic morpholo-
gical and functional imaging can provide. Additionally,
visualization of these processes would provide more pre-
cise information about the disease expansion. Beyond that,
novel therapy regimens such as immunotherapies require
methods for tracking the therapeutic cells. Different ima-
ging modalities are used for these purposes, originally
established in cell biology labs like fluorescence imaging
(FLI), bioluminescence imaging (BLI), and photoacoustic
imaging (PAI) as well as in clinical routine like magnetic
resonance imaging (MRI), computed tomography (CT),
positron emission tomography (PET), single photon emis-
sion CT (SPECT), and ultrasound (US).
Variations in endogenous tissue contrast can be uti-
lized for certain applications, e. g. alterations in oxygen
saturation lead to signal changes in PAI and dedicated
MRI sequences like BOLD sequences. However, specific
contrast agents need to be designed in most assignments.
These molecules usually consist of a targeting moiety
that binds to molecules of interest, indicates certain func-
tional states of the tissue, or is modified by specific
enzymes on the one hand. On the other hand, another
moiety is needed that changes tissue contrast in order to
be detected by the chosen modality, like fluorophores for
FLI, microbubbles for US, e.g. gadolinium for MRI, e.g.
18F for PET and e.g. 99mTc for SPECT. These contrast
agents can either be injected into the animals whereby
pharmacokinetics of the molecule itself determines the
imaging protocol. Alternatively, they can be used for cell
labelling in order to track these cells after injection into
the animals. Most of these techniques in general provide
the opportunity to be translated into clinical routine.
This toolbox of endogenous and exogenous contrast
agents is completed by reporter gene imaging that
allows detecting changes in gene expression. This tech-
nique is in most cases limited to preclinical imaging. To
visualize changes of gene expression, genetic sequences
are used that code for different fluorescent proteins for
FLI, different luciferases for BLI, herpes simplex virus
tyrosine kinase (hsv-tk) for PET or e.g. iron-binding or
iron-storage proteins for MRI. These gene sequences are
brought under the control of the promoter of interest.
The vectors constructed this way are then either trans-
fected into tumor cells for preclinical transplantation
models of cancer or used for the generation of trans-
genic animals.
Pancreatic ductal adenocarcinoma (PDAC) represents
one of the malignancies with the poorest prognosis where
incidence equals mortality. Despite considerable advances
in the understanding of the molecular mechanisms
involved in the carcinogenesis of PDAC during the last
decade the survival of the disease was not significantly
improved over the last 40 years. Therefore, novel thera-
peutic approaches are urgently needed. Preclinical animal
imaging can provide accurate measures of tumor progres-
sion non-invasively. Molecular imaging can in addition
help, a) to detect cellular and molecular processes in vivo
avoiding artefacts caused by tissue collection and preserva-
tion, b) to visualize specific therapy effects on certain
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signalling pathways over time, and c) to reduce animal
numbers needed due to its non-invasiveness.
PDAC is characterized by early spreading of metastatic
cells and a high rate of local and distant recurrent dis-
ease even after complete surgical removal of the primary
lesion as defined by histology. One key factor for this
aggressiveness seems to be due to the high susceptibility
towards inflammatory signals, part of which are acting
in an autocrine manner since PDAC cells have been
found to frequently express simultaneously ligands and
corresponding receptors. From a surgical point of view
local recurrent disease as well as distant metastases
(mostly in the liver) limit the success of this curative
therapeutic attempt, for which less then 20% of patients
are eligible. There is strong evidence that inflammation
drives these sometimes rapid and fulminant recurrences.
Adjuvant chemotherapy has been shown to improve the
outcome yet no long-term survival is achieved. Numer-
ous different contrast agents for all modalities are avail-
able to detect surrogate markers of inflammation, such
as endothelial adhesion molecules like E-selectin or
VCAM, as well as enzymatic activity e.g. of matrix
metalloproteases, caspases or cathepsins. Additionally,
invasion of immune cells can be monitored by reporter
gene imaging.
A plethora of molecular alterations are thought to be
responsible for the profound chemoresistance. Besides
classical hallmarks of cancer such as mutations in the
K-ras oncogene and the p53 tumor suppressor, the consti-
tutive or inducible activity of transcription factor pathways
is characteristic for PDAC. The nuclear factor-B (NF-B)
has been shown besides others to be crucial for tumor
development and apoptosis resistance mechanisms in this
context. We have shown that NF-B contributes to non-
apoptotic signalling of death receptors, “normally” indu-
cing apoptosis upon death-ligand-driven activation. Thus,
targeting this pathway by established recombinant inhibi-
tors or new drugs including natural compounds with anti-
inflammatory potential might have great potential for
future therapeutic concepts.
In summary, in vivo animal models are a key element
of understanding the processes of tumor development
and progression as well as of validating novel strategies
for tumor therapies. Clinically adapted animal models
allow distinguishing between adjuvant, palliative and
neo-adjuvant concepts. Preclinical animal imaging and
especially molecular imaging can help to visualize mole-
cular and cellular processes during the course of the dis-
ease non-invasively in vivo, and will allow a more valid
validation of any novel therapeutic regime.
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